{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:17:23Z","timestamp":1791328643988,"version":"4.3.1"},"reference-count":91,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"DOI":"10.1086\/491710","type":"journal-article","created":{"date-parts":[[2005,12,5]],"date-time":"2005-12-05T10:26:15Z","timestamp":1133778375000},"page":"S13-S24","source":"Crossref","is-referenced-by-count":203,"title":["Microbiological Features of Vancomycin in the 21st Century: Minimum Inhibitory Concentration Creep, Bactericidal\/Static Activity, and Applied Breakpoints to Predict Clinical Outcomes or Detect Resistant Strains"],"prefix":"10.1093","volume":"42","author":[{"given":"Ronald N.","family":"Jones","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2006,1,1]]},"reference":[{"key":"key\n\t\t\t\t20171014000410_ref1","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.3201\/eid1011.040797_10","article-title":"Methicillin-resistant Staphylococcus aureus","volume":"10","author":"Tenover","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref2","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1128\/AAC.42.5.1303","article-title":"Historical yearly usage of vancomycin","volume":"42","author":"Kirst","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(88)91037-9","article-title":"Vancomycin-resistant enterococci","volume":"1","author":"Uttley","year":"1988","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014000410_ref4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/10766290152652774","article-title":"Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci","volume":"7","author":"Woodford","year":"2001","journal-title":"Microb Drug Resist"},{"key":"key\n\t\t\t\t20171014000410_ref5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-2003-37923","article-title":"Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997\u20132001)","volume":"24","author":"Jones","year":"2003","journal-title":"Semin Respir Crit Care Med"},{"key":"key\n\t\t\t\t20171014000410_ref6","volume-title":"Teicoplanin, the first decade","author":"Wilson APR, Gruneberg RN","year":"1997"},{"key":"key\n\t\t\t\t20171014000410_ref7","article-title":"Methods of dilution antimicrobial susceptibility tests for bacteria that grow aerobically","volume-title":"Report no. M7-A6","author":"NCCLS","year":"2003"},{"key":"key\n\t\t\t\t20171014000410_ref8","article-title":"Performance standards for antimicrobial disc susceptibility tests","volume-title":"15th informational supplement","author":"Clinical Laboratory Standards Institute","year":"2005"},{"key":"key\n\t\t\t\t20171014000410_ref9","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1128\/AAC.47.10.3040-3045.2003","article-title":"Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods","volume":"47","author":"Liu","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref10","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1128\/JCM.39.7.2439-2444.2001","article-title":"Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides","volume":"39","author":"Walsh","year":"2001","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014000410_ref11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.micro.56.012302.160806","article-title":"The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus","volume":"56","author":"Walsh","year":"2002","journal-title":"Annu Rev Microbiol"},{"key":"key\n\t\t\t\t20171014000410_ref12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/47.4.399","article-title":"A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital","volume":"47","author":"Wootton","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1128\/AAC.30.5.633","article-title":"Problems in in vitro determination of antibiotic tolerance in clinical isolates","volume":"30","author":"Sherris","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/AAC.30.4.521","article-title":"Antibiotic tolerance among clinical isolates of bacteria","volume":"30","author":"Tuomanen","year":"1986","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1128\/AAC.23.1.138","article-title":"Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981","volume":"23","author":"Farber","year":"1983","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref16","article-title":"Pharmacodynamic evaluation of teicoplanin versus vancomycin in the treatment of Gram-positive bacteremia and endocarditis [abstract A36]","volume-title":"Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans)","author":"Rybak","year":"1996"},{"key":"key\n\t\t\t\t20171014000410_ref17","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/AAC.48.11.4427-4429.2004","article-title":"Evidence for biliary excretion of vancomycin into stool during intravenous therapy: potential implications for rectal colonization with vancomycin-resistant enterococci","volume":"48","author":"Currie","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref18","first-page":"626, 635","article-title":"Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20171014000410_ref19","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/jama.1993.03500050076029","article-title":"The epidemiology of intravenous vancomycin usage in a university hospital: a 10-year study","volume":"269","author":"Ena","year":"1993","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171014000410_ref20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/1120009X.1993.11739203","article-title":"Trends in gram-positive bloodstream organism resistance: a seven-year audit of five glycopeptides and other drugs at a large university hospital","volume":"5","author":"Ena","year":"1993","journal-title":"J Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref21","doi-asserted-by":"crossref","first-page":"4240","DOI":"10.1128\/AAC.48.11.4240-4245.2004","article-title":"Evolution of the antimicrobial resistance of Staphylococcus spp. in Spain: five nationwide prevalence studies, 1986 to 2002","volume":"48","author":"Cuevas","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref22","first-page":"624","article-title":"Reduced susceptibility of Staphylococcus aureus to vancomycin\u2014Japan, 1996","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20171014000410_ref23","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(97)07324-8","article-title":"Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin","volume":"350","author":"Hiramatsu","year":"1997","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014000410_ref24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/jac\/40.1.135","article-title":"Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility","volume":"40","author":"Hiramatsu","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinte.1958.00260140229033","article-title":"The sensitivity of staphylococci to antibiotics: a five-year study of sensitivity, usage, and cross resistance in a general hospital","volume":"101","author":"Waisbren","year":"1958","journal-title":"AMA Arch Intern Med"},{"key":"key\n\t\t\t\t20171014000410_ref26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2004.09.005","article-title":"Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin","volume":"51","author":"Rybak","year":"2005","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1086\/501605","article-title":"The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis","volume":"20","author":"Garrett","year":"1999","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20171014000410_ref28","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1056\/NEJM198704093161507","article-title":"Emergence of vancomycin resistance in coagulase-negative staphylococci","volume":"316","author":"Schwalbe","year":"1987","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014000410_ref29","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s100960050380","article-title":"Presence of Staphylococcus aureus with reduced susceptibility to vancomycin in Germany","volume":"18","author":"Bierbaum","year":"1999","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/jac\/dkf142","article-title":"Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features","volume":"50","author":"Denis","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref31","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(05)79166-2","article-title":"First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital","volume":"351","author":"Ploy","year":"1998","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014000410_ref32","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1128\/JCM.38.2.866-869.2000","article-title":"Heterogeneous vancomycin resistance in methicillin-resistant Staphylococcus aureus strains isolated in a large Italian hospital","volume":"38","author":"Marchese","year":"2000","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014000410_ref33","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/jac\/dkf252","article-title":"The first Staphylococcus aureus isolates with reduced susceptibility to vancomycin in Poland","volume":"50","author":"Krzyszton-Russjan","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1086\/501932","article-title":"Isolation in Brazil of nosocomial Staphylococcus aureus with reduced susceptibility to vancomycin","volume":"22","author":"Oliveira","year":"2001","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20171014000410_ref35","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1128\/JCM.38.10.3879-3881.2000","article-title":"Vancomycin-intermediate Staphylococcus aureus in Korea","volume":"38","author":"Kim","year":"2000","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014000410_ref36","first-page":"1165","article-title":"Staphylococcus aureus with reduced susceptibility to vancomycin\u2014Illinois, 1999","volume":"48","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20171014000410_ref37","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1086\/317542","article-title":"Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know","volume":"32","author":"Fridkin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1086\/346207","article-title":"Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997\u20132001","volume":"36","author":"Fridkin","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref39","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/JCM.36.4.1020-1027.1998","article-title":"Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides","volume":"36","author":"Tenover","year":"1998","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014000410_ref40","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM199902183400704","article-title":"The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection","volume":"340","author":"Sieradzki","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014000410_ref41","first-page":"1","article-title":"Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep","year":"2001"},{"key":"key\n\t\t\t\t20171014000410_ref42","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/BF01967563","article-title":"Structure, biochemistry and mechanism of action of glycopeptide antibiotics","volume":"8","author":"Reynolds","year":"1989","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1128\/JCM.41.1.5-14.2003","article-title":"Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus","volume":"41","author":"Cui","year":"2003","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014000410_ref44","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1128\/AAC.44.9.2276-2285.2000","article-title":"Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50","volume":"44","author":"Cui","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref45","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJM199902183400701","article-title":"Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group","volume":"340","author":"Smith","year":"1999","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014000410_ref46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/jac\/42.2.199","article-title":"Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50","volume":"42","author":"Hanaki","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref47","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/381093","article-title":"Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus","volume":"38","author":"Charles","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref48","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/381202","article-title":"Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility","volume":"38","author":"Howden","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref49","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1128\/AAC.47.4.1262-1266.2003","article-title":"Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis","volume":"47","author":"Moore","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref50","first-page":"565","article-title":"Staphylococcus aureus resistant to vancomycin\u2014United States, 2002","volume":"51","author":"Sievert","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20171014000410_ref51","first-page":"902","article-title":"Vancomycin-resistant Staphylococcus aureus\u2014Pennsylvania, 2002","volume":"51","author":"Miller","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20171014000410_ref52","first-page":"322","article-title":"Vancomycin-resistant Staphylococcus aureus\u2014New York, 2004","volume":"53","author":"Kacica","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key\n\t\t\t\t20171014000410_ref53","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa025025","article-title":"Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene","volume":"348","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014000410_ref54","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1128\/AAC.47.12.3954-3959.2003","article-title":"Plasmid content of a vancomycin-resistant Enterococcus faecalis isolate from a patient also colonized by Staphylococcus aureus with a VanA phenotype","volume":"47","author":"Flannagan","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref55","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1126\/science.1090956","article-title":"Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus","volume":"302","author":"Weigel","year":"2003","journal-title":"Science"},{"key":"key\n\t\t\t\t20171014000410_ref56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1128\/AAC.48.1.275-280.2004","article-title":"Vancomycin-resistant Staphylococcus aureus isolate from a patient in Pennsylvania","volume":"48","author":"Tenover","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref57","doi-asserted-by":"crossref","first-page":"4281","DOI":"10.1128\/AAC.48.11.4281-4285.2004","article-title":"Heterologous expression of the enterococcal vanA operon in methicillin-resistant Staphylococcus aureus","volume":"48","author":"Perichon","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref58","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1086\/382357","article-title":"Vancomycin-resistant Staphylococcus aureus in the absence of vancomycin exposure","volume":"38","author":"Whitener","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref59","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1574-6968.1992.tb05089.x","article-title":"Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus","volume":"72","author":"Noble","year":"1992","journal-title":"FEMS Microbiol Lett"},{"key":"key\n\t\t\t\t20171014000410_ref60","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1086\/382366","article-title":"Vancomycin-resistant Staphylococcus aureus in the clinic: not quite Armageddon","volume":"38","author":"Bush","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref61","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/jac\/dkg457","article-title":"Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center","volume":"52","author":"Bozdogan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref62","first-page":"12","article-title":"Definition of terms \u201cresistant\u201d and \u201csusceptible.\u201d","volume-title":"The antimicrobic susceptibility test: principles and practices","author":"Barry","year":"1976"},{"key":"key\n\t\t\t\t20171014000410_ref63","article-title":"Performance standards for antimicrobial disc susceptibility tests: tentative standard","volume-title":"Report no. M2-T","author":"NCCLS","year":"1974"},{"key":"key\n\t\t\t\t20171014000410_ref64","article-title":"Performance standards for antimicrobial disc susceptibility tests: first supplement","volume-title":"Report no. M2-A2S","author":"NCCLS","year":"1981"},{"key":"key\n\t\t\t\t20171014000410_ref65","article-title":"Performance standards for antimicrobial disk susceptibility tests: approved standard","volume-title":"Report no. M2-A8","author":"NCCLS","year":"2003","edition":"8th ed"},{"key":"key\n\t\t\t\t20171014000410_ref66","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jac\/44.5.675","article-title":"Expression and detection of hetero-vancomycin resistance in Staphylococcus aureus","volume":"44","author":"Howe","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref67","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1128\/JCM.37.11.3590-3593.1999","article-title":"Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals","volume":"37","author":"Hubert","year":"1999","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014000410_ref68","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0732-8893(92)90121-9","article-title":"Diffusion of teicoplanin and vancomycin in agar","volume":"15","author":"Cavenaghi","year":"1992","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref69","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1128\/JCM.25.9.1812-1814.1987","article-title":"Quality control limits for teicoplanin susceptibility tests and confirmation of disk diffusion interpretive criteria","volume":"25","author":"Barry","year":"1987","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014000410_ref70","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1128\/JCM.23.1.100-103.1986","article-title":"Evaluation of teicoplanin and vancomycin disk susceptibility tests","volume":"23","author":"Barry","year":"1986","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014000410_ref71","article-title":"Failure of automated systems to detect vancomycin-resistant Staphylococcus aureus [abstract D-66]","volume-title":"Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC)","author":"Carey","year":"2004"},{"key":"key\n\t\t\t\t20171014000410_ref72","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-115-9-674","article-title":"Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis","volume":"115","author":"Levine","year":"1991","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20171014000410_ref73","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/227138a0","article-title":"Multiple antibiotic resistance in a bacterium with suppressed autolytic system","volume":"227","author":"Tomasz","year":"1970","journal-title":"Nature"},{"key":"key\n\t\t\t\t20171014000410_ref74","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1128\/AAC.6.6.825","article-title":"Evidence for participation of autolysins in bactericidal action of oxacillin on Staphylococcus aureus","volume":"6","author":"Best","year":"1974","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref75","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/AAC.10.4.707","article-title":"Variation in the susceptibility of strains of Staphylococcus aureus to oxacillin, cephalothin, and gentamicin","volume":"10","author":"Mayhall","year":"1976","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref76","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0140-6736(77)91941-9","article-title":"A new type of penicillin resistance of Staphylococcus aureus","volume":"1","author":"Sabath","year":"1977","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171014000410_ref77","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/clinids\/7.3.368","article-title":"Antibiotic tolerance among clinical isolates of bacteria","volume":"7","author":"Handwerger","journal-title":"Rev Inf Dis"},{"key":"key\n\t\t\t\t20171014000410_ref78","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1128\/AAC.46.5.1492-1502.2002","article-title":"Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin","volume":"46","author":"Sakoulas","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref79","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1086\/368128","article-title":"Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance?","volume":"187","author":"Sakoulas","year":"2003","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref80","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014000410_ref81","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1086\/421092","article-title":"Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy","volume":"38","author":"Moise-Broder","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref82","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1128\/AAC.48.3.1024-1027.2004","article-title":"Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II","volume":"48","author":"Verdier","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref83","article-title":"Heterogeneous glycopeptide resistance in Staphylococcus aureus associated with accessory gene regulatory (agr) group II [abstract 123]","volume-title":"Program and abstracts of the annual meeting of the American College of Clinical Pharmacy (Dallas)","author":"Tsuji","year":"2004"},{"key":"key\n\t\t\t\t20171014000410_ref84","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1128\/AAC.49.2.857-859.2005","article-title":"Activity of glycopeptides against Staphylococcus aureus infection in a rabbit endocarditis model: MICs do not predict in vivo efficacy","volume":"49","author":"Asseray","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref85","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1089\/mdr.2004.10.346","article-title":"A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections","volume":"10","author":"Domenech","year":"2004","journal-title":"Microb Drug Resist"},{"key":"key\n\t\t\t\t20171014000410_ref86","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1086\/425009","article-title":"The importance of bactericidal drugs: future directions in infectious disease","volume":"39","author":"Finberg","year":"2004","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref87","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijantimicag.2004.04.006","article-title":"Activity of daptomycin against multi-resistant Gram-positive bacteria including enterococci and Staphylococcus aureus resistant to linezolid","volume":"24","author":"Johnson","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171014000410_ref88","first-page":"1178","article-title":"Special phenotypic methods for detecting antibacterial resistance","volume-title":"Manual of clinical microbiology","author":"Swenson","year":"2003","edition":"8th ed."},{"key":"key\n\t\t\t\t20171014000410_ref89","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1128\/AAC.45.2.454-459.2001","article-title":"Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations","volume":"45","author":"Akins","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014000410_ref90","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.diagmicrobio.2004.06.014","article-title":"Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline","volume":"50","author":"LaPlante","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014000410_ref91","article-title":"Evaluation of FDA-approved disk diffusion breakpoint for daptomycin [abstract D-48]","volume-title":"Program and abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington, DC)","author":"Jevitt","year":"2004"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/42\/Supplement_1\/S13\/20906964\/42-Supplement_1-S13.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,11]],"date-time":"2020-04-11T06:36:59Z","timestamp":1586587019000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/42\/Supplement_1\/S13\/275219\/Microbiological-Features-of-Vancomycin-in-the-21st"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":91,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2006,1,1]]},"published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1086\/491710","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13485000.14862121","asserted-by":"object"}]},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,1,1]]},"published":{"date-parts":[[2006,1,1]]}}}